Your browser doesn't support javascript.
loading
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon, Jonathan S; Gore, Martin; Thompson, John F; Davis, Ian D; McArthur, Grant A; Walpole, Euan; Smithers, Mark; Cerundolo, Vincenzo; Dunbar, P Rod; MacGregor, Duncan; Fisher, Cyril; Millward, Michael; Nathan, Paul; Findlay, Michael P N; Hersey, Peter; Evans, T R Jeffry; Ottensmeier, Christian Hermann; Marsden, Jeremy; Dalgleish, Angus G; Corrie, Pippa G; Maria, Marples; Brimble, Margaret; Williams, Geoff; Winkler, Sintia; Jackson, Heather M; Endo-Munoz, Liliana; Tutuka, Candani S A; Venhaus, Ralph; Old, Lloyd J; Haack, Dennis; Maraskovsky, Eugene; Behren, Andreas; Chen, Weisan.
Affiliation
  • Cebon JS; Cancer Immunobiology Programme, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University at Austin Health, Heidelberg, Victoria, Australia j.cebon@onjcri.org.au.
  • Gore M; Ludwig Institute for Cancer Research Austin Branch, Heidelberg, Victoria, Australia.
  • Thompson JF; Oncology, Royal Marsden Hospital NHS Trust, London, UK.
  • Davis ID; Melanoma Institute Australia, North Sydney, New South Wales, Australia.
  • McArthur GA; Ludwig Institute for Cancer Research Austin Branch, Heidelberg, Victoria, Australia.
  • Walpole E; Monash University Eastern Health Clinical School, Box Hill, Victoria, Australia.
  • Smithers M; Melanona and Skin Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Cerundolo V; Cancer Services Division, Princess Alexandra Hospital Health Service District, Woolloongabba, Queensland, Australia.
  • Dunbar PR; Oncology Services Unit, Princess Alexandra Hospital Health Service District, Woolloongabba, Queensland, Australia.
  • MacGregor D; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
  • Fisher C; School of Biological Sciences and Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Millward M; Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia.
  • Nathan P; Oncology, Royal Marsden Hospital NHS Trust, London, UK.
  • Findlay MPN; School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
  • Hersey P; Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, London, UK.
  • Evans TRJ; School of Medicine and Health Science, The University of Auckland, Auckland, New Zealand.
  • Ottensmeier CH; Melanoma Immunology and Oncology Group, Centenary Institute, Newtown, New South Wales, Australia.
  • Marsden J; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Dalgleish AG; School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton, Hampshire, UK.
  • Corrie PG; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Maria M; Cell and Molecular Sciences, Division of Oncology, St Georges Hospital Medical School, London, UK.
  • Brimble M; West Anglia Cancer Research Network Oncology Centre, Addenbrooke's Hospital, Cambridge, Cambridgeshire, UK.
  • Williams G; The Cancer Research Centre, Weston Park Hospital, Sheffield, UK.
  • Winkler S; School of Biological Sciences and Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Jackson HM; School of Biological Sciences and Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Endo-Munoz L; School of Biological Sciences and Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Tutuka CSA; Ludwig Institute for Cancer Research Austin Branch, Heidelberg, Victoria, Australia.
  • Venhaus R; Cancer Immunobiology Programme, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University at Austin Health, Heidelberg, Victoria, Australia.
  • Old LJ; Cancer Immunobiology Programme, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University at Austin Health, Heidelberg, Victoria, Australia.
  • Haack D; Ludwig Institute for Cancer Research Austin Branch, Heidelberg, Victoria, Australia.
  • Maraskovsky E; Ludwig Institute for Cancer Research, New York, New York, USA.
  • Behren A; Ludwig Institute for Cancer Research, New York, New York, USA.
  • Chen W; Versagenics Inc, Morrisville, North Carolina, USA.
J Immunother Cancer ; 8(1)2020 04.
Article in En | MEDLINE | ID: mdl-32317292
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phospholipids / Saponins / Skin Neoplasms / Adjuvants, Immunologic / Cholesterol / Cancer Vaccines / Melanoma / Neoplasm Recurrence, Local Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phospholipids / Saponins / Skin Neoplasms / Adjuvants, Immunologic / Cholesterol / Cancer Vaccines / Melanoma / Neoplasm Recurrence, Local Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Year: 2020 Type: Article